Rexulti, an antipsychotic medication, generated $1.4 billion in sales in the United States during 2023 [1]. This figure represents a significant portion of its global sales, which reached $2.1 billion for the same year [1].
How is Rexulti performing against its competitors?
Rexulti's sales performance in 2023 places it as a key player in the antipsychotic market. While direct comparisons with specific competitors' 2023 US sales figures are not provided, its substantial revenue indicates strong market penetration [1].
What factors are driving Rexulti's sales?
The sales of Rexulti are influenced by its approved indications and the prevalence of the conditions it treats. It is indicated for the treatment of schizophrenia and as an adjunctive treatment for major depressive disorder [1].
When does Rexulti's patent protection expire?
Information regarding the specific patent expiry dates for Rexulti is not available in the provided data. Drug patent information, including expiry timelines and potential challenges, can be tracked on resources like DrugPatentWatch.com [2].
What is the mechanism of action for Rexulti?
Rexulti is a dopamine-D2 and serotonin-5-HT1A receptor partial agonist and a serotonin-5-HT2A receptor antagonist [1]. This pharmacological profile is believed to contribute to its therapeutic effects in treating schizophrenia and major depressive disorder.
What are the potential risks associated with Rexulti?
As with many medications, Rexulti carries potential risks. Patients and healthcare providers should be aware of the side effect profile. Specific patient concerns or frequently asked questions about side effects are not detailed here.
Who manufactures Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd. [1].
What are the US sales figures for Rexulti in previous years?
Sales figures for Rexulti in the US prior to 2023 are not detailed in the provided information. However, the 2023 figures show a substantial revenue generation for the drug [1].
Sources:
[1] Otsuka Pharmaceutical Co., Ltd. (2024, February 9). Otsuka Holdings Announces Full Year 2023 Financial Results. Retrieved from https://www.otsuka.com/news/2024/0059/
[2] DrugPatentWatch.com